Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement
Etanercept as intensification therapy for KD with coronary artery aneurysms can be delivered safely and with good compliance. This report suggests benefit in preventing long-term persistence of severe and any coronary artery disease.
Authors
- Michael A. Portman (ORCID: https://orcid.org/0000-0002-8168-3725)
- Aaron Olson (ORCID: https://orcid.org/0000-0002-5237-400X)
- Eyal Sagiv (ORCID: https://orcid.org/0000-0002-7010-7722)
- Ryan Rogers
Institutions
- Seattle Children's Hospital (US)
Publication Details
- Journal
- The Journal of Pediatrics Clinical Practice
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.jpedcp.2025.200165
- Primary Topic
- Kawasaki Disease and Coronary Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00